Sign In
Buy AKBA
$0.97
+0.0333 (+3.56%)
At Close: Jun 03, 2026
Akebia Therapeutics to Report First Quarter 2021 Financial Results and Discuss Recent Business Highlights
08:00am, Wednesday, 28'th Apr 2021
CAMBRIDGE, Mass., April 28, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today
NEW YORK, April 26, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 02'nd Apr 2021
CAMBRIDGE, Mass., April 2, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, grant
Akebia (AKBA) Files NDA for Vadadustat for Anemia Due to CKD
10:36am, Wednesday, 31'st Mar 2021
Akebia (AKBA) submits new drug application for vadadustat to treat anemia due to chronic kidney disease in adult patients who are on dialysis as well as who are not on dialysis.
CAMBRIDGE, Mass., March 30, 2021 /PRNewswire/ -- Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease,
CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced that its collaboration partner, Japan Tobacco Inc. (JT), received approval from the Pharma
Akebia Therapeutics Celebrates World Kidney Day and National Kidney Month
08:00am, Thursday, 11'th Mar 2021
CAMBRIDGE, Mass., March 11, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, cele
Bumble, NextEra Energy, Wheaton Precious Metals and More Monday Afternoon Analyst Calls
12:20pm, Monday, 08'th Mar 2021
With the trading day about halfway over, the broad markets were pushing higher on the day.
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q4 2020 Results - Earnings Call Transcript
11:56pm, Thursday, 25'th Feb 2021
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q4 2020 Results - Earnings Call Transcript
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
01:41pm, Thursday, 18'th Feb 2021
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen, 3D Systems, Duke Energy, Ford and More of Friday Afternoon's Analyst Calls
03:34pm, Friday, 29'th Jan 2021
With the trading day practically over, the broad markets were sliding into the weekend.
Implied Volatility Surging for Akebia Therapeutics (AKBA) Stock Options
09:47am, Wednesday, 16'th Dec 2020
Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.
AkebiaShares Program: Current Approaches for Managing Hyperphosphatemia and Caring for Patients via Telehealth
08:00am, Wednesday, 09'th Dec 2020
CAMBRIDGE, Mass., Dec. 9, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today an
Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™
09:37am, Wednesday, 18'th Nov 2020
CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today a
CAMBRIDGE, Mass., Nov. 16, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today a
